Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,619.00+4.31%ETH$2,425.59+6.71%GOLD$4,072.70-0.01%OIL$88.34+0.25%
Smart Investors Daily
SID Premium
EN

NASDAQ · ENLV

Enlivex Therapeutics Ltd.

Healthcare · Biotechnology

$1.46

Down-$0.07 (-4.79%)

Updated Nov 5, 2026, 12:15 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.6M
P/E ratio
-1.84
Dividend yield
0.00%
52-week range
$0.19 – $8.12
Volume
37.97K
Avg. volume
3.73M

Price performance · ENLV

ENLV price history

1M range · 0 trading sessions · Daily adjusted prices

ENLV does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ENLV news

The latest Smart Investors Daily articles mentioning ENLV.

Stock researchCompany · Overview

ENLV research

Overview

Company profile and research snapshot.

Company profile

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
ENLV recent ratings
DateFirmRatingTarget
Aug 3, 2026HC Wainwright & Co.Buy—
Apr 7, 2026HC Wainwright & Co.Buy—
Jan 12, 2026HC Wainwright & Co.Buy—
Nov 24, 2025D. Boral CapitalHold—
Oct 29, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

• 135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe • Topline six-month data expected by mid-2027 • Phase 2b builds on positive three- and six-month Phase 1/2a data, which supported FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted in July 2026 Nes-Ziona, Israel, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By